All Infection Prevention & Control articles – Page 12
-
NewsCancer medication helps reduce SIV reservoir, increases hope for HIV cure
Researchers have provided the first proof-of-concept in a nonhuman primate model for eliminating HIV-infected cells with venetoclax, a clinically approved medication for cancer.
-
NewsERC Starting Grant for Tom Beneke: Drug resistance in tropical parasites
Molecular biologist Dr Tom Beneke (35) from the Biozentrum at the University of Würzburg has been awarded a €1.5 million ERC grant to further advance his research on Leishmania and the disease they cause.
-
NewsInvasive mosquito species detected in east London
The UK Health Security Agency (UKHSA) is undertaking enhanced surveillance and trapping activities following the detection of invasive Aedes aegypti mosquitoes and larvae at nearby residential properties in east London.
-
NewsImmune drug anifrolumab linked to lower risk of infection and hospitalization for skin lupus
Preliminary results from an investigator-initiated single-site clinical study show that some people with chronic cutaneous lupus erythematosus are less likely to acquire life-threatening infections when taking the drug anifrolumab.
-
NewsNew design strategy expands nanoparticle vaccine approach to influenza viruses
Research scientists have developed a blueprint for stabilizing key influenza proteins and using them to make next-generation vaccine candidates.
-
NewsAntifungal therapy shows potential for IBD patients with candida overgrowth
A commonly used systemic antifungal medication may help reduce symptoms in a subset of patients with inflammatory bowel disease (IBD) by restoring a healthier gut microbiome, according to a preliminary study.
-
NewsAnti-influenza therapies that target the host
Researchers suggest that nucleolin-binding drugs are a promising avenue of research in the quest to overcome drug resistance and improve influenza management worldwide.
-
NewsGoniothalamin as a dual-target medicinal chemistry candidate against antibiotic-resistant bacteria
A new computational study has found that goniothalamin — a natural plant compound — binds tightly to two critical bacterial proteins in drug-resistant Staphylococcus aureus and Escherichia coli, suggesting it could form the basis of a new class of antibacterial agents.
-
NewsPediatric investigation review emphasizes the evolving landscape of pediatric enterovirus infections
A review article highlights how rapid viral evolution of enteroviruses combined with shifting dominant strains and antigenic variation present a major obstacle to EV prevention and control in children.
-
NewsSemen facilitates infection with mpox virus
Researchers have found that seminal fluid can facilitate infection of skin cells with the mpox virus. An analysis of the seminal fluid showed that certain naturally occurring protein fragments are responsible for this effect.
-
NewsStudy finds that cognitive decline after omicron infection is largely reversible
Cognitive problems, often described as “brain fog,” are a recognized feature of long COVID, affecting attention, memory, and executive function. Earlier SARS-CoV-2 variants, including the original strain, Alpha and Delta, were associated with persistent cognitive deficits. However, the Omicron variant caused less severe disease, leaving uncertainty about whether cognitive decline ...
-
NewsA full-control strategy could cut simulated mpox infections by 97.8%, suggests mathematical model
Researchers have used mathematical modeling to explore how different interventions could work together to limit Mpox transmission. The model captures Mpox transmission dynamics across two interacting populations: humans and rodents.
-
NewsA bacterial protein fragment drives tissue fibrosis, but antibody treatment can help
A bacterial protein fragment called corisin drives the process of pulmonary fibrosis by infiltrating and disrupting the cell’s quality-control system, researchers found in a new study. Meanwhile, blocking corisin with an antibody impeded the damage.
-
NewsRECOVER-VITAL clinical trial finds no benefit of extended duration of PAXLOVID for Long COVID
Results from a clinical trial show that the antiviral drug, PAXLOVID, commonly prescribed to treat acute COVID-19, does not have an impact on Long COVID symptoms when compared to placebo.
-
NewsResearcher awarded two NIH grants to advance research on antibiotic-resistant infections
The research is focused on developing new strategies to combat two infectious diseases: catheter-associated urinary tract infections (CAUTIs) and invasive Group A Streptococcus skin infections, both of which are increasingly difficult to treat because of antimicrobial resistance.
-
NewsT cells are a powerful force against Zika virus
Scientists tested two Zika vaccines in a study that brings them one step closer to a “pan-orthoflavivirus vaccine”, which could teach T cells to fight several viruses at once.
-
NewsDietary tryptophan prevents sepsis
Dietary tryptophan protects against sepsis through gut microbiota-derived metabolites which enhance macrophage bacterial phagocytosis.
-
NewsImmune responses to urinary tract infection linked to birth outcomes
A new study shows that the increased risk of preterm pregnancies associated with urinary tract infection, is linked to the body’s immune response to the infection rather than to the bacteria themselves.
-
NewsFor Legionella bacteria, taking over a cell means playing by its rules
New research demonstrates how a protein produced by Legionella mimics the behavior of the host cell’s own proteins.
-
NewsTuberculosis transmission may hold the key to prevention
Scientists have discovered the specific mechanisms that enable the bacteria responsible for tuberculosis to not only survive drying but also to generate mutations linked to antibiotic resistance.